OPTRUMA Side Effects

6905233-8 | Investigation, Pulmonary Embolism
on Jul 22, 2010 Female patient from GERMANY , 79 years of age, was diagnosed with osteoporosis (What is osteoporosis?), hypertensive heart disease, chronic obstructive pulmonary disease and was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: investigation, pulmonary embolism (What is pulmonary embolism?). Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with LEXATIN (1.5 Mg, Unk) (View Lexatin Review and Lexatin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), SINTROM (View Sintrom Review and Sintrom Label ), SPIRIVA (View Spiriva Review and Spiriva Label ), ZALDIAR (Unk D/f, Unk) (View Zaldiar Review and Zaldiar Label ). Patient was hospitalized.

6883406-0 | Cerebral Ischaemia
Patient was taking Optruma (View Usage). Patient had the following side effects: cerebral ischaemia on Jul 16, 2010 from FRANCE Additional patient health information: Female patient , weighting 121.3 lb, was diagnosed with osteoporosis (What is osteoporosis?) and. Optruma dosage: 1 D/f, Daily (1/d). During the same period patient was treated with OROCAL D(3) (View Orocal D(3) Review and Orocal D(3) Label ). Patient was hospitalized.

6749895-7 | Coagulopathy, Leukaemia, Phlebitis
Adverse event was reported on May 18, 2010 by a Female patient taking Optruma (View Usage) (Dosage: ) . Location: FRANCE , 50 years of age, After Optruma was administered, patient had the following side effects: coagulopathy, leukaemia, phlebitis.

6497484-4 | Uterine Polyp
on Dec 02, 2009 Female patient from FRANCE , 67 years of age, weighting 123.5 lb, was diagnosed with osteopenia, hypertension and was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: uterine polyp. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with OROCAL (View Orocal Review and Orocal Label ), LERCANIDIPINE (View Lercanidipine Review and Lercanidipine Label ), COLPOTROPHINE (View Colpotrophine Review and Colpotrophine Label ).


6469264-7 | Breast Discomfort, Hypothyroidism, Weight Increased
on Apr 25, 2008 Female patient from FRANCE , 55 years of age, was diagnosed with osteoporosis (What is osteoporosis?), blood cholesterol abnormal and was treated with Optruma (View Usage). Patient had the following side effects: breast discomfort, hypothyroidism, weight increased. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with CACIT D3 (Unk, Unk) (View Cacit D3 Review and Cacit D3 Label ), TAHOR (1 D/f, Daily (1/d)) (View Tahor Review and Tahor Label ).

6462505-1 | Uterine Polyp
Patient was taking Optruma (View Usage). After Optruma was administered, patient had the following side effects: uterine polyp on Nov 17, 2009 from FRANCE Additional patient health information: Female patient , 67 years of age, was diagnosed with osteopenia and. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with OROCAL (View Orocal Review and Orocal Label ), LERCANIDIPINE (View Lercanidipine Review and Lercanidipine Label ), COLPOTROPHINE (View Colpotrophine Review and Colpotrophine Label ).

6386718-2 | Depression, Fall, Joint Sprain, Retinal Haemorrhage, Retinal Vein Occlusion
Adverse event was reported on May 05, 2008 by a Female patient taking Optruma (View Usage) (Dosage: 60 Mg, Daily (1/d)) was diagnosed with osteoporosis (What is osteoporosis?) and. Location: FRANCE , weighting 123.5 lb, Patient experienced the following unwanted or unexpected effects: depression (What is depression?), fall (What is fall?), joint sprain, retinal haemorrhage, retinal vein occlusion. During the same period patient was treated with VASTAREL (View Vastarel Review and Vastarel Label ), KARDEGIC (View Kardegic Review and Kardegic Label ), INDOCOLLYRE (View Indocollyre Review and Indocollyre Label ), TRUSOPT (View Trusopt Review and Trusopt Label ), VOLTAREN (Unk, Unk) (View Voltaren Review and Voltaren Label ), ARTOTEC (View Artotec Review and Artotec Label ), DI ANTALVIC (Unk, As Needed) (View Di-antalvic Review and Di-antalvic Label ).

6377442-0 | Breast Cancer
on Sep 15, 2009 Female patient from FRANCE , 76 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and was treated with Optruma (View Usage). Patient had the following side effects: breast cancer (What is breast cancer?). Optruma dosage: . During the same period patient was treated with RALOXIFENE HYDROCHLORIDE (Unk, Unk) (View Raloxifene Hydrochloride Review and Raloxifene Hydrochloride Label ).

6360384-4 | Breast Cancer Stage Iii
on Sep 07, 2009 Female patient from FRANCE , 62 years of age, weighting 138.9 lb, was diagnosed with osteopenia and was treated with Optruma (View Usage). After Optruma was administered, patient had the following side effects: breast cancer stage iii. Optruma dosage: 1 D/f, Daily (1/d). Patient was hospitalized.

6272212-6 | Cerebral Arteriosclerosis, Ischaemic Cerebral Infarction
Patient was taking Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral arteriosclerosis, ischaemic cerebral infarction on Jul 08, 2009 from FRANCE Additional patient health information: Female patient , 66 years of age, weighting 119.0 lb, was diagnosed with osteoporosis (What is osteoporosis?) and. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with CACIT D3 (1 D/f, Daily (1/d)) (View Cacit D3 Review and Cacit D3 Label ), SEROPLEX (20 Mg, Daily (1/d)) (View Seroplex Review and Seroplex Label ), TANAKAN (2 D/f, 2/d) (View Tanakan Review and Tanakan Label ). Patient was hospitalized.

6271070-3 | Retinal Haemorrhage, Retinal Vein Occlusion
Adverse event was reported on Jul 04, 2008 by a Female patient taking Optruma (View Usage) (Dosage: 60 Mg, Daily (1/d)) was diagnosed with osteoporosis (What is osteoporosis?) and. Location: FRANCE , weighting 123.5 lb, Patient had the following side effects: retinal haemorrhage, retinal vein occlusion. During the same period patient was treated with VASTAREL (View Vastarel Review and Vastarel Label ), KARDEGIC (View Kardegic Review and Kardegic Label ), INDOCOLLYRE (View Indocollyre Review and Indocollyre Label ), TRUSOPT (View Trusopt Review and Trusopt Label ).

6254776-1 | Cerebral Arteriosclerosis, Ischaemic Cerebral Infarction
on Jun 22, 2009 Female patient from FRANCE , 67 years of age, was treated with Optruma (View Usage). After Optruma was administered, patient had the following side effects: cerebral arteriosclerosis, ischaemic cerebral infarction. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with CACIT D3 (View Cacit D3 Review and Cacit D3 Label ), SEROPLEX (View Seroplex Review and Seroplex Label ), TANAKAN (View Tanakan Review and Tanakan Label ). Patient was hospitalized.

6108958-X | Endometrial Cancer Stage I
on Feb 24, 2009 Female patient from FRANCE , 66 years of age, weighting 110.2 lb, was diagnosed with osteoporosis (What is osteoporosis?) and was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: endometrial cancer stage i. Optruma dosage: 1 D/f, Daily (1/d). During the same period patient was treated with HORMONES NOS (View Hormones Nos Review and Hormones Nos Label ).

6079398-7 | Erythema Nodosum
Patient was taking Optruma (View Usage). Patient had the following side effects: erythema nodosum on Feb 03, 2009 from FRANCE Additional patient health information: Female patient , 62 years of age, . Optruma dosage: 1 D/f, Daily (1/d).

6033093-9 | Breast Cancer, Malaise, Thrombocytopenia, Tumour Marker Increased
Adverse event was reported on Dec 18, 2008 by a Female patient taking Optruma (View Usage) (Dosage: ) was diagnosed with osteoporosis (What is osteoporosis?) and. Location: FRANCE , 71 years of age, After Optruma was administered, patient had the following side effects: breast cancer (What is breast cancer?), malaise, thrombocytopenia, tumour marker increased. During the same period patient was treated with CALCIDOSE (View Calcidose Review and Calcidose Label ), MUTAGRIP (View Mutagrip Review and Mutagrip Label ).

6025521-X | Breast Cancer
on Dec 19, 2008 Female patient from FRANCE , 61 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: breast cancer (What is breast cancer?). Optruma dosage: 1 D/f, Daily (1/d). Patient was hospitalized.

5973617-0 | Hepatic Function Abnormal
on Nov 18, 2008 Female patient from SPAIN , 53 years of age, was diagnosed with osteopenia and was treated with Optruma (View Usage). Patient had the following side effects: hepatic function abnormal. Optruma dosage: 60 Mg, Daily (1/d).

5955718-6 | Endometrial Cancer Stage I
Patient was taking Optruma (View Usage). After Optruma was administered, patient had the following side effects: endometrial cancer stage i on Nov 04, 2008 from FRANCE Additional patient health information: Female patient , 66 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and. Optruma dosage: . During the same period patient was treated with HORMONES NOS (View Hormones Nos Review and Hormones Nos Label ).

5944620-1 | Thrombocytopenia, Transaminases Increased
Adverse event was reported on Oct 24, 2008 by a Female patient taking Optruma (View Usage) (Dosage: 60 Mg, Unk) was diagnosed with osteopenia and. Location: PORTUGAL , 57 years of age, Patient experienced the following unwanted or unexpected effects: thrombocytopenia, transaminases increased. During the same period patient was treated with BENZODIAZEPINE DERIVATIVES (View Benzodiazepine Derivatives Review and Benzodiazepine Derivatives Label ). Patient was hospitalized.

5903852-9 | Dystonia
on Sep 17, 2008 Female patient from FRANCE , 61 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and was treated with Optruma (View Usage). Patient had the following side effects: dystonia (What is dystonia?). Optruma dosage: . During the same period patient was treated with SEROPLEX (View Seroplex Review and Seroplex Label ).

5899701-8 | Cervix Carcinoma
on Sep 12, 2008 Female patient from FRANCE , 79 years of age, weighting 105.8 lb, was diagnosed with kyphosis and was treated with Optruma (View Usage). After Optruma was administered, patient had the following side effects: cervix carcinoma. Optruma dosage: . During the same period patient was treated with IDEOS (1 D/f, Daily (1/d)) (View Ideos Review and Ideos Label ), FLUDEX (1 D/f, Daily (1/d)) (View Fludex Review and Fludex Label ).

5816813-5 | Uterine Cancer
Patient was taking Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: uterine cancer (What is uterine cancer?) on Jul 11, 2008 from FRANCE Additional patient health information: Female patient , 58 years of age, weighting 103.6 lb, was diagnosed with osteoporosis (What is osteoporosis?), anxiety (What is anxiety?), muscle spasms, constipation (What is constipation?) and. Optruma dosage: Unk, Daily (1/d). During the same period patient was treated with LEXOMIL (1 D/f, Daily (1/d)) (View Lexomil Review and Lexomil Label ), HEXAQUINE (2 D/f, Daily (1/d)) (View Hexaquine Review and Hexaquine Label ), MOVICOL (2 D/f, Daily (1/d)) (View Movicol Review and Movicol Label ). Patient was hospitalized.

5788008-5 | Uterine Cancer
Adverse event was reported on Jun 13, 2008 by a Female patient taking Optruma (View Usage) (Dosage: Unk, Daily (1/d)) . Location: FRANCE , 57 years of age, Patient had the following side effects: uterine cancer (What is uterine cancer?). During the same period patient was treated with ANTINEOPLASTIC AGENTS (View Antineoplastic Agents Review and Antineoplastic Agents Label ).

5779420-9 | Breast Enlargement, Ocular Hypertension, Visual Acuity Reduced
on Jun 06, 2008 Female patient from FRANCE , 60 years of age, was treated with Optruma (View Usage). After Optruma was administered, patient had the following side effects: breast enlargement, ocular hypertension, visual acuity reduced. Optruma dosage: .

5732480-3 | Breast Discomfort, Hypothyroidism, Weight Increased
on Apr 25, 2008 Female patient from FRANCE , 55 years of age, was diagnosed with osteoporosis (What is osteoporosis?), blood cholesterol abnormal and was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: breast discomfort, hypothyroidism, weight increased. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with CACIT D3 (Unk, Unk) (View Cacit D3 Review and Cacit D3 Label ), TAHOR (1 D/f, Daily (1/d)) (View Tahor Review and Tahor Label ).

5727818-7 | Retinal Vascular Thrombosis
Patient was taking Optruma (View Usage). Patient had the following side effects: retinal vascular thrombosis on Apr 23, 2008 from FRANCE Additional patient health information: Female patient , 60 years of age, . Optruma dosage: .

5675244-1 | Breast Cancer In Situ
Adverse event was reported on Mar 10, 2008 by a Female patient taking Optruma (View Usage) (Dosage: ) . Location: FRANCE , 74 years of age, After Optruma was administered, patient had the following side effects: breast cancer in situ. Patient was hospitalized.

5657462-1 | Retinal Vein Thrombosis
on Feb 27, 2008 Female patient from FRANCE , 68 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: retinal vein thrombosis. Optruma dosage: 1 D/f, Daily (1/d). Patient was hospitalized.

5600607-X | Coronary Artery Stenosis
on Jan 11, 2008 Female patient from FRANCE , 60 years of age, was treated with Optruma (View Usage). Patient had the following side effects: coronary artery stenosis. Optruma dosage: 60 Mg, Daily (1/d). Patient was hospitalized.

5571601-2 | Arterial Thrombosis
Patient was taking Optruma (View Usage). After Optruma was administered, patient had the following side effects: arterial thrombosis on Dec 18, 2007 from SPAIN Additional patient health information: Female patient , 50 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and. Optruma dosage: . During the same period patient was treated with NATECAL D (View Natecal D Review and Natecal D Label ). Patient was hospitalized.

5456470-3 | Endometrial Cancer
Adverse event was reported on Sep 03, 2007 by a Female patient taking Optruma (View Usage) (Dosage: 60 Mg, Daily (1/d)) . Location: FRANCE , 57 years of age, Patient experienced the following unwanted or unexpected effects: endometrial cancer. Patient was hospitalized.

5365715-X | Uterine Cancer
on Jun 08, 2007 Female patient from FRANCE , 57 years of age, was treated with Optruma (View Usage). Patient had the following side effects: uterine cancer (What is uterine cancer?). Optruma dosage: Unk, Daily (1/d).

5346381-6 | Choking Sensation, Pruritus, Urticaria Localised
on May 23, 2007 Female patient from , 59 years of age, was treated with Optruma (View Usage). After Optruma was administered, patient had the following side effects: choking sensation, pruritus, urticaria localised. Optruma dosage: 60 Mg, Daily (1/d).

5338733-5 | Endometrial Cancer
Patient was taking Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: endometrial cancer on May 23, 2007 from FRANCE Additional patient health information: Female patient , 60 years of age, . Optruma dosage: 60 Mg, Daily (1/d).

5316142-2 | Retinal Vascular Thrombosis
Adverse event was reported on Apr 23, 2007 by a Female patient taking Optruma (View Usage) (Dosage: 60 Mg, Daily (1/d)) was diagnosed with osteoporosis (What is osteoporosis?) and. Location: FRANCE , 68 years of age, weighting 123.5 lb, Patient had the following side effects: retinal vascular thrombosis.

5219353-X | Back Pain, Dermatitis Bullous, Hepatocellular Damage
on Jan 12, 2007 Female patient from FRANCE , 57 years of age, was diagnosed with osteoporosis (What is osteoporosis?), back pain (What is back pain?), oesophagitis, varicose vein (What is varicose vein?), arthropathy and was treated with Optruma (View Usage). After Optruma was administered, patient had the following side effects: back pain (What is back pain?), dermatitis bullous, hepatocellular damage. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with KETOPROFEN (100 Mg, Daily (1/d)) (View Ketoprofen Review and Ketoprofen Label ), PROPOFOL (3 D/f, Daily (1/d)) (View Propofol Review and Propofol Label ), GAVISCON (3 D/f, Daily (1/d)) (View Gaviscon Review and Gaviscon Label ), ENDOTELON (150 Mg, 2/d) (View Endotelon Review and Endotelon Label ), CHONDROSULF (400 Mg, 2/d) (View Chondrosulf Review and Chondrosulf Label ), OMEPRAZOLE (20 Mg, Daily (1/d)) (View Omeprazole Review and Omeprazole Label ), STALEVO 100 (Unk, 4/d) (View Stalevo 100 Review and Stalevo 100 Label ), MODOPAR (125 Mg, 2/d) (View Modopar Review and Modopar Label ). Patient was hospitalized.

5158585-6 | Detachment Of Retinal Pigment Epithelium, Optic Atrophy, Retinal Disorder
on Nov 20, 2006 Female patient from ITALY , 70 years of age, was treated with Optruma (View Usage). Patient experienced the following unwanted or unexpected effects: detachment of retinal pigment epithelium, optic atrophy, retinal disorder (What is retinal disorder?). Optruma dosage: 1 D/f, Daily (1/d).

5150844-6 | Breast Cancer, Pulmonary Embolism
Patient was taking Optruma (View Usage). Patient had the following side effects: breast cancer (What is breast cancer?), pulmonary embolism (What is pulmonary embolism?) on Mar 02, 2006 from FRANCE Additional patient health information: Female patient , 58 years of age, was diagnosed with osteoporosis (What is osteoporosis?) and. Optruma dosage: 60 Mg, Daily (1/d). During the same period patient was treated with ART 50 (View Art 50 Review and Art 50 Label ), ERCEFURYL (View Ercefuryl Review and Ercefuryl Label ). Patient was hospitalized and became disabled.